RVL Pharmaceuticals plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- RVL Pharmaceuticals, Inc. operates as a specialty pharmaceutical firm, concentrating on the advancement and commercialization of products addressing unmet needs within the ocular and medical aesthetics fields. The company's principal offering is Upneeq (oxymetazoline hydrochloride ophthalmic solution) 0.1%, an FDA-approved prescription treatment designed for adults experiencing acquired blepharoptosis, commonly known as low-lying eyelids. This innovative solution represents the first non-surgical approach available for this condition. Originally operating as Osmotica Pharmaceuticals plc, the company underwent a strategic rebranding to RVL Pharmaceuticals plc in January 2022, shifting its focus predominantly to eye care and medical aesthetics. RVL Pharmaceuticals distinguishes its commercial model through direct sales, an in-house pharmacy, and a cash-pay approach, effectively streamlining the traditional pharmaceutical value chain. This strategy aims to provide accessible solutions to healthcare providers, including optometrists, ophthalmologists, and aesthetic specialists, and to patients in regions such as the United States, Argentina, and Hungary. The company supports its commercial efforts with its e-commerce platform, Elevate, facilitating patient prescriptions and subscription services. In a significant corporate development, the U.S. operating subsidiaries successfully completed a financial restructuring in November 2023, while the former RVL Pharmaceuticals plc (the Irish entity) has commenced wind-down procedures, with its public equity anticipated to be cancelled during 2024. RVL Pharmaceuticals, Inc. maintains its operational base in Bridgewater, New Jersey.
Osmotica Pharma Announces Rebranding As RVL Pharma, Issues Q4 Sales Outlook
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q3 2021 Results - Earnings Call Transcript
Osmotica Pharmaceuticals (OSMT) Reports Q3 Loss, Misses Revenue Estimates
Osmotica Pharmaceuticals plc to Present at Jefferies London Virtual Healthcare Conference 2021
Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering
OSMT Stock: Why It Fell By Over 35% This Week
Here's why Osmotica Pharmaceuticals is down 35% on Thursday
Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million
OSMT Stock: Why It Substantially Fell Today
Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering
Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering
Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q2 2021 Results - Earnings Call Transcript
Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021
Osmotica Pharmaceuticals plc to Provide Second Quarter 2021 Business and Financial Update on August 16, 2021